High prevalence of spin was found in pharmacovigilance studies using disproportionality analyses to detect safety signals: a meta-epidemiological study.


Journal

Journal of clinical epidemiology
ISSN: 1878-5921
Titre abrégé: J Clin Epidemiol
Pays: United States
ID NLM: 8801383

Informations de publication

Date de publication:
10 2021
Historique:
received: 12 03 2021
revised: 13 06 2021
accepted: 22 06 2021
pubmed: 30 6 2021
medline: 30 11 2021
entrez: 29 6 2021
Statut: ppublish

Résumé

To systematically review and appraise misinterpretation of pharmacovigilance disproportionality analysis results in published studies. We randomly selected 100 studies that performed disproportionality analyses and indexed in Medline identified during a systematic literature search. Titles, abstracts and main texts (results, discussion and conclusion) were evaluated for spin independently by two reviewers. Spin in pharmacovigilance studies was classified according to three main categories: inappropriate interpretation, inappropriate extrapolations and misleading reporting. Of the 100 studies evaluated, we found that 63%, 56% and 51% had at least one type of spin in their abstract, main text or conclusion respectively, and 40% used causal language to interpret their results in the abstract or conclusion. Spin in titles and results were exclusively represented by inappropriate interpretations of findings (12% and 21% respectively), with terms such as "risk of" or "risks associated with" or results erroneously presented as regular Odds Ratios. Spin in discussion sections mostly concerned inappropriate interpretations (38%)and misleading reporting (12%). Misleading reporting, notably failing to acknowledge the limitations of disproportionality analyses, was the most frequent type of spin in abstracts (55%) and conclusion sections (37%). We found that spin is frequent in publications of pharmacovigilance disproportionality analyses, notably in abstracts. This consisted notably in an over-interpretation of the results suggesting a proven causative link between a drug use and the risk of an event.

Identifiants

pubmed: 34186195
pii: S0895-4356(21)00200-6
doi: 10.1016/j.jclinepi.2021.06.022
pii:
doi:

Types de publication

Journal Article Meta-Analysis

Langues

eng

Sous-ensembles de citation

IM

Pagination

73-79

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Auteurs

Amelle Mouffak (A)

Pharmacovigilance Unit, Grenoble Alpes University Hospital, Grenoble F-38000, France.

Marion Lepelley (M)

Pharmacovigilance Unit, Grenoble Alpes University Hospital, Grenoble F-38000, France.

Bruno Revol (B)

Pharmacovigilance Unit, Grenoble Alpes University Hospital, Grenoble F-38000, France; HP2 Laboratory, INSERM U1042, University Grenoble Alpes, Grenoble F-38000, France.

Claire Bernardeau (C)

Pharmacovigilance Unit, Grenoble Alpes University Hospital, Grenoble F-38000, France.

Francesco Salvo (F)

Pharmacoepidemiology Team Bordeaux Population Health INSERM U1219, University of Bordeaux, Bordeaux F-33000, France; Medical Pharmacology Unit, Public Health division, Bordeaux University Hospital (CHU), Bordeaux 33000, France.

Antoine Pariente (A)

Pharmacoepidemiology Team Bordeaux Population Health INSERM U1219, University of Bordeaux, Bordeaux F-33000, France; Medical Pharmacology Unit, Public Health division, Bordeaux University Hospital (CHU), Bordeaux 33000, France.

Matthieu Roustit (M)

HP2 Laboratory, INSERM U1042, University Grenoble Alpes, Grenoble F-38000, France; Clinical Pharmacology Department INSERM CIC 1406, Grenoble Alpes University Hospital, Grenoble F-38000, France.

Jean-Luc Cracowski (JL)

Pharmacovigilance Unit, Grenoble Alpes University Hospital, Grenoble F-38000, France; HP2 Laboratory, INSERM U1042, University Grenoble Alpes, Grenoble F-38000, France.

Charles Khouri (C)

Pharmacovigilance Unit, Grenoble Alpes University Hospital, Grenoble F-38000, France; HP2 Laboratory, INSERM U1042, University Grenoble Alpes, Grenoble F-38000, France; Clinical Pharmacology Department INSERM CIC 1406, Grenoble Alpes University Hospital, Grenoble F-38000, France. Electronic address: CKhouri@chu-grenoble.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH